AD2C

Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) platform enables the seamless integration of various linker-payload types through a site-selective conjugation process, ensuring high conjugation efficiency while preserving antibody binding capacity.
AD2C also offers flexibility in adjusting the Drug-to-Antibody Ratio (DAR) to align with specific treatment objectives. Its sophisticated dual-payload design effectively addresses the tumor heterogeneity often encountered in traditional mono-payload Antibody-Drug Conjugate (ADC) products.
Additionally, AD2C can incorporate validated linker-payloads without requiring complex antibody engineering, making it an excellent platform candidate for ADC drug discovery.